J 2010

IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status

JEŽÍŠKOVÁ, Ivana, Filip RÁZGA, Monika BAJEROVÁ, Zdeněk RÁČIL, Jiří MAYER et. al.

Basic information

Original name

IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status

Authors

JEŽÍŠKOVÁ, Ivana (203 Czech Republic, guarantor), Filip RÁZGA (703 Slovakia, belonging to the institution), Monika BAJEROVÁ (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution)

Edition

Leukemia & Lymphoma, Gordon and Breach, 2010, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.492

RIV identification code

RIV/00216224:14110/10:00067242

Organization unit

Faculty of Medicine

DOI

UT WoS

000285004300021

Keywords in English

acute myeloid leukemia

Tags

International impact, Reviewed
Změněno: 25/4/2014 13:05, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

In conclusion, our data demonstrate that, within the cohort of tested individuals, the IDH2 mutations are associated with AML (in contrast to healthy volunteers), suggesting a role for these mutations in disease pathogenesis. In addition, we show an association of the observed IDH2 mutations with disease status, indicating their potential for MRD monitoring. This report thus indicates that IDH2 p.R140 variants are possible markers for MRD detection. However, an extended investigation of IDH2 mutations kinetics, involving long-term followup and a larger cohort of IDH2 mutated AMLs, will be required to confirm these findings.